好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Skin Alpha-Synuclein Seed Amplification Assay for Diagnosis of Parkinson’s Disease and Other Synucleinopathies
Movement Disorders
P1 - Poster Session 1 (8:00 AM-9:00 AM)
16-014
To determine the sensitivity and specificity of an alpha-synuclein seed amplification assay (αSyn-SAA) using skin punch biopsy for diagnosis of Parkinson's disease (PD) and non-PD synucleinopathies (DLB and MSA) relative to normal controls.

Disease-associated aggregated alpha-synuclein was found in peripheral tissues in PD, including skin. RT-QuIC-based αSyn-SAA with CSF had high sensitivity and specificity for PD diagnosis in prior studies, but skin offers a less invasive and more easily accessible tissue.

Following written informed consent, we obtained skin punch biopsies from 158 living participants; 95 with PD (21 possible PD and 74 probable PD, by UK Brain Bank criteria), 17 other synucleinopathies (8 DLB and 9 MSA), and 46 controls.  Bilateral 4mm biopsies were lateral to the C7 vertebra except for 6 subjects biopsied 15cm above the patella. Endpoint Thioflavin T fluorescence values (ThT), a measure of αSyn-seeding activity in RT-QuIC, was measured. Using an optimal ThT cutoff of 64,750, assay sensitivity and specificity values were calculated for each sub-group.  Welch 2-sample t-test was used to compare mean age and Chi-Squared Test to compare percentage of females.  

In PD versus controls, mean(SD) age was 69.41(9.11) versus 66.39(8.53) (p=0.057) and percentage of females was 42.11% versus 69.56% (p=0.004). In PD, median Hoehn&Yahr score (N=94) was 2.0, mean(SD) MDS-UPDRS Part 3 (N=93) was 32.04(10.92) and total MDS-UPDRS (N=93) was 50.82(19.02). 3/46 of the controls were positive by the biopsy skin αSyn-SAA (or SAA+), corresponding to 93.5% specificity. In comparison, 82.1% (78/95) of PD cases and 82.4% (14/17) of non-PD parkinsonism cases were SAA+.  Sensitivity was 85.1% in probable PD as opposed to 71.4% in possible PD.  

Our biopsy skin αSyn-SAA differentiated PD and non-PD synucleinopathies from controls with ~82% sensitivity and 93.5% specificity, supporting its potential as a less invasive biomarker for diagnosis of PD and non-PD parkinsonism.
Authors/Disclosures
Steven A. Gunzler, MD, FAAN (Parkinson's and Movement Disorders Ctr, University Hospitals)
PRESENTER
Dr. Gunzler has received research support from NIH/NINDS. Dr. Gunzler has received research support from Parkinson's Foundation. The institution of Dr. Gunzler has received research support from UCB. The institution of Dr. Gunzler has received research support from Bial.
Yueqi Wang, undergraduate student Ms. Wang has nothing to disclose.
Irene Litvan, MD, FAAN (UC San Diego Parkinson and Other Movement Disorder Center) Dr. Litvan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aprinoia. Dr. Litvan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Litvan has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology. Dr. Litvan has received personal compensation in the range of $50,000-$99,999 for serving as a Chief Editor with Frontiers in Neurology.
Huaihou Chen, PhD Mr. Chen has nothing to disclose.
Mohamed Elkasaby, MD Dr. Elkasaby has nothing to disclose.
Alexander Wang, MD (University Hospitals Cleveland Medical Center) Dr. Wang has nothing to disclose.
Temitope A. Lawal, MD (Neurology, ECU health) Dr. Lawal has nothing to disclose.
Allie C. Toth, MD (University of Michigan Health - West) Dr. Patterson has nothing to disclose.
Jeng Shi Kong Mr. Kong has nothing to disclose.